CPI 613
drugOn this page
Also known as Cpi-613CPI613DevimistatSID174007465
Summary
Cpi 613 (CHEMBL3186849) is a phase-3 clinical-stage small molecule; indicated across 11 conditions including acute myeloid leukemia and exocrine pancreatic carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 11 conditions
- Clinical trials: 31
- Chemistry: 388.6 Da · C22H28O2S2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3186849 |
| Name | CPI 613 |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 24770514 |
| ChEBI | CHEBI:233958 |
| Molecular formula | C22H28O2S2 |
| Molecular weight | 388.6 |
| InChIKey | ZYRLHJIMTROTBO-UHFFFAOYSA-N |
SMILES: C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
IUPAC name: 6,8-bis(benzylsulfanyl)octanoic acid
ChEBI definition: An organic sulfide that is 6,8-bis(mercapto)octanoic acid in which the two thiol groups at positions 6 and 8 are substituted by benzyl groups.
Also known as: Cpi 613, CPI 613, Cpi-613, CPI613, Devimistat, SID174007465, CPI-613
Patent coverage: 209 distinct patent families (595 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| acute myeloid leukemia | 3 | MONDO:0018874 | EFO:0000222 |
| exocrine pancreatic carcinoma | 3 | MONDO:0005192 | EFO:0002618 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| leukemia | 2 | MONDO:0005059 | EFO:0000565 |
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| pancreatic ductal adenocarcinoma | 2 | MONDO:0005184 | MONDO:0005184 |
| sarcoma | 1 | MONDO:0005089 | EFO:0000691 |
| colorectal neoplasm | 1 | MONDO:0005335 | EFO:0004142 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 31.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 11 |
| PHASE2 | 10 |
| PHASE1/PHASE2 | 9 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03504423 | PHASE3 | COMPLETED | Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas |
| NCT03793140 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations |
| NCT05733000 | PHASE2 | RECRUITING | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors |
| NCT00907166 | PHASE1/PHASE2 | TERMINATED | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients |
| NCT01520805 | PHASE2 | WITHDRAWN | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome |
| NCT01766219 | PHASE1/PHASE2 | COMPLETED | CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery |
| NCT01830322 | PHASE2 | WITHDRAWN | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer |
| NCT01832857 | PHASE2 | TERMINATED | Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients |
| NCT01902381 | PHASE2 | TERMINATED | CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy |
| NCT02472626 | PHASE1/PHASE2 | WITHDRAWN | 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia |
| NCT03370159 | PHASE1/PHASE2 | WITHDRAWN | CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer |
| NCT03374852 | PHASE2 | WITHDRAWN | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer |
| NCT03699319 | PHASE1/PHASE2 | COMPLETED | CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer |
| NCT03929211 | PHASE1/PHASE2 | WITHDRAWN | CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome |
| NCT04203160 | PHASE1/PHASE2 | TERMINATED | Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) |
| NCT04217317 | PHASE2 | TERMINATED | CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma |
| NCT04593758 | PHASE1/PHASE2 | COMPLETED | To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue |
| NCT05854966 | PHASE2 | WITHDRAWN | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| NCT05926206 | PHASE1/PHASE2 | WITHDRAWN | Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas |
| NCT06518538 | PHASE2 | WITHDRAWN | Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer |
| NCT00741403 | PHASE1 | COMPLETED | A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies |
| NCT01034475 | PHASE1 | COMPLETED | Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies |
| NCT01768897 | PHASE1 | COMPLETED | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| NCT01835041 | PHASE1 | COMPLETED | CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer |
| NCT01839981 | PHASE1 | COMPLETED | CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| NCT01931787 | PHASE1 | COMPLETED | CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer |
| NCT02168140 | PHASE1 | COMPLETED | CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
| NCT02168907 | PHASE1 | TERMINATED | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma |
| NCT02232152 | PHASE1 | COMPLETED | CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery |
| NCT02484391 | PHASE1 | COMPLETED | CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma |
| NCT05070104 | PHASE1 | WITHDRAWN | CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).